Critical tests of morantel-trichlorfon paste formulation against internal parasites of the horse.
Critical tests were completed on six horses to evaluate the antiparasitic activity of a paste formulation mixture of morantel citrate and trichlorfon, administered intraorally at the dose rate of 6 mg morantel base kg-1 and trichlorfon at 30 mg kg-1. Aggregate average removals were: 78% for two horses infected with 2nd instar Gasterophilus intestinalis; 100% for one infected with 2nd instar G. nasalis; 96% for six infected with 3rd instar G. intestinalis; 100% for four infected with 3rd instar G. nasalis; 100% for five infected with Parascaris equorum; 100% for one infected with mature Oxyuris equi; 100% for five infected with Strongylus vulgaris; 72% for five infected with S. edentatus; and partial removal (25%) of Anoplocephala perfoliata infection from one infected animal. Pre- and post-treatment EPG and LPG data indicated a reduction of 97% of the mature small strongyle infections. Evidence of toxicosis was not observed in any of the horses.
D000818:Animals; D001199:Ascaridoidea; D002590:Cestode Infections / Q000188:drug therapy / Q000662:veterinary*; D004341:Drug Evaluation / Q000662:veterinary; D004359:Drug Therapy, Combination / Q000662:veterinary; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D009015:Morantel / Q000008:administration & dosage*; D009198:Myiasis / Q000662:veterinary*; D009349:Nematode Infections / Q000188:drug therapy / Q000662:veterinary*; D009824:Ointments; D010123:Oxyuriasis / Q000188:drug therapy / Q000662:veterinary; D011743:Pyrimidines / Q000008:administration & dosage*; D013319:Strongyle Infections, Equine / Q000188:drug therapy; D014236:Trichlorfon / Q000008:administration & dosage*
D009824:Ointments; D011743:Pyrimidines; D009015:Morantel; D014236:Trichlorfon